Prostate cancer screening: A racial dichotomy

Archives of Internal Medicine

Volumn 164, Issue 17, 2004, Pages 1830-1832

  Calsoyas, Isis ^b   Stratton, M Suzanne ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; AGE; ANTIGEN DETECTION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; DIAGNOSTIC ACCURACY; EDITORIAL; GENETIC SUSCEPTIBILITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; MEDICAID; MEDICAL EXAMINATION; MEDICARE; POVERTY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; RACE DIFFERENCE; SCREENING TEST; SOCIOECONOMICS; TESTOSTERONE BLOOD LEVEL;

AFRICAN AMERICANS; AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PATIENT COMPLIANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 4644241040     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.17.1830     Document Type: Editorial

References (16)

1. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003:53:27-43.
2. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med. 2002;162:1985-1993.
3. Gilligan T, Wang PS, Levin R, Kantoff PW, Avorn J. Racial differences in screening for prostate cancer in the elderly. Arch Intern Med. 2004;164:1858-1864.
4. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004;13:R103-R121.
5. Eastham JA, May RA, Whatley T, Crow A, Venable DD, Sartor O. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst. 1998;90:756-760.
6. Winters SJ, Brufsky A, Weissfeld J, Trump DL, Dyky MA, Hadeed V. Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism. 2001;50:1242-1247.
7. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer, receiver operating characteristic curves. J Urol. 1994;152:2031-2036.
8. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002;29:173-181.
9. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality, II: individual countries. BJU Int. 2002;90:174-184.
10. Bishop MC. Trends in prostate cancer mortality in England, Wales, and the USA. Lancet Oncol. 2000;1:14.
11. Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin Urol Oncol. 2002;20:3-9.
12. Etzioni R, Berry KM, Legier JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology. 2002; 59:251-255.
13. Cooper GS, Yuan Z, Jethva RN, Rimm AA. Use of Medicare claims data to measure county-level variation in breast carcinoma incidence and mammography rates. Cancer Detect Prev. 2002;26:197-202.
14. Cooper GS, Yuan Z, Jethva RN, Rimm AA. Determination of county-level prostate carcinoma incidence and detection rates with Medicare claims data. Cancer: 2001;92:102-109.
15. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62:3-12.
16. Smith DS, Bullock AD, Catalona WJ, Herschman JD. Racial differences in a prostate cancer screening study. J Urol. 1996;156:1366-1369.